Bookmark and Share
BioAssay: AID 1469

qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2

Thyroid receptor (TR) regulates many homeostatic processes including basal metabolism, cardiovascular function, body weight, and lipid trafficking. TR modulators are potential therapeutics for obesity and hyperlipidemias but current thyroid analogs have undesirable side effects, particularly cardiac stimulation. To identify inhibitors that specifically prevent the interaction of TR with the more ..
_
   
 Tested Compounds
 Tested Compounds
All(276277)
 
 
Active(177)
 
 
Inactive(275143)
 
 
Inconclusive(1019)
 
 
 Tested Substances
 Tested Substances
All(282587)
 
 
Active(183)
 
 
Inactive(281374)
 
 
Inconclusive(1030)
 
 
AID: 1469
Data Source: NCGC (TR778)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2008-12-31

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 177
Related Experiments
Show more
AIDNameTypeProbeComment
1485Quantitative High-Throughput Screen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2: SummarySummary depositor-specified cross reference
1567Cell-based Gene Reporter Secondary Assay to Characterize qHTS Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
1568Cell Viability Secondary Assay to Characterize qHTS Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
1570Concentration Response Confirmation Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2, Fluorescein FluoroprobeConfirmatory depositor-specified cross reference
1573Concentration Response Confirmation Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
2444Protein Interaction Secondary Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2, Alpha ScreenConfirmatory depositor-specified cross reference
2447Cell Viability Secondary Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
2448Androgen Receptor Selectivity Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
2449PPAR gamma Selectivity Assay For Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
2455Vitamin D Receptor Selectivity Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory depositor-specified cross reference
2479Gene Reporter Secondary Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 in a Thyroid Receptor AssayConfirmatory depositor-specified cross reference
2487Secondary Confirmation Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2, Fluorescein FluoroprobeConfirmatory depositor-specified cross reference
2490Secondary Confirmation Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2, Texas Red FluoroprobeConfirmatory depositor-specified cross reference
2512qHTS Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2: Probe SummarySummary1 depositor-specified cross reference
2552Irreversible Binding Assay for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Other depositor-specified cross reference
1479Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory same project related to Summary assay
1479Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2Confirmatory same project related to Summary assay
1571Total Fluorescence Confirmation Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2, Fluorescein FluoroprobeConfirmatory same project related to Summary assay
Description:
NIH Molecular Libraries Probe Production Network [MLPCN]
NIH Chemical Genomics Center [NCGC]

MLPCN Grant: DK058080
Assay Provider: R. Kip Guy, St. Jude Children's Research Hospital

NCGC Assay Overview:
Thyroid receptor (TR) regulates many homeostatic processes including basal metabolism, cardiovascular function, body weight, and lipid trafficking. TR modulators are potential therapeutics for obesity and hyperlipidemias but current thyroid analogs have undesirable side effects, particularly cardiac stimulation. To identify inhibitors that specifically prevent the interaction of TR with the steroid receptor coregulator 2 (SRC2), a fluorescence polarization assay was screened. This assay detects interaction of the ligand-binding domain of human TRb with a Texas Red labeled SRC2 peptide, corresponding to a 20 amino acid region of the nuclear receptor interaction domain (Arnold et al., 2006). Small molecule inhibitors that block the interaction of TR and SRC2 are detected by a decrease in fluorescence polarization.

Arnold, L. A.; Estebanez-Perpina, E.; Togashi, M.; Shelat, A.; Ocasio, C. A.; McReynolds, A. C.; Nguyen, P.; Baxter, J. D.; Fletterick, R. J.; Webb, P.; Guy, R. K. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE 2006, p 13.
Protocol
NCGC Assay Protocol Summary:
For screening, 5 uL/well 0.6 uM TRb and 20 nM SRC2 Texas Red in protein buffer (20mM Tris hydrochloride, 100mM NaCl, 10% glycerol, 1mM EDTA, 0.01% NP-40, 1mM DTT, 1uM T3 and 5% DMSO) was dispensed into black solid 1536-well plates (Grenier) using a solenoid-based dispenser. Following transfer of 23 nL compound or DMSO vehicle by a pin tool, the plates were centrifuged 15 s at 1000 RPM and incubated 5 hr at ambient temperature. The plates were read by an Envision (Perkin Elmer) to detect fluorescence polarization of SRC2 Texas Red (555 nm excitation and 632 nm emission). Data were normalized to unbound (all components except TRb) and bound SRC2 Texas Red controls. In this assay, we provide % activity data for each concentration as well as potencies for the active compounds.
Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, qHTS, thyroid hormone receptor, steroid receptor coactivator, fluorescence polarization
Comment
Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Categorized Comment - additional comments and annotations
From ChEMBL:
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1PhenotypeIndicates type of activity observed: inhibitor, activator, fluorescent, cytotoxic, inactive, or inconclusive.String
2Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
3EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
4Analysis CommentAnnotation/notes on a particular compound's data or its analysis.String
5Curve_DescriptionA description of dose-response curve quality. A complete curve has two observed asymptotes; a partial curve may not have attained its second asymptote at the highest concentration tested. High efficacy curves exhibit efficacy greater than 80% of control. Partial efficacies are statistically signficant, but below 80% of control.String
6Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
7Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
8Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
9Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
10Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
11Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
12Excluded_PointsWhich dose-response titration points were excluded from analysis based on outlier analysis. Each number represents whether a titration point was (1) or was not (0) excluded, for the titration series going from smallest to highest compound concentrations.String
13Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
14Activity at 0.00132 uM (0.00131982μM**)% Activity at given concentration.Float%
15Activity at 0.00295 uM (0.00295015μM**)% Activity at given concentration.Float%
16Activity at 0.00660 uM (0.00659908μM**)% Activity at given concentration.Float%
17Activity at 0.015 uM (0.0147495μM**)% Activity at given concentration.Float%
18Activity at 0.031 uM (0.0311951μM**)% Activity at given concentration.Float%
19Activity at 0.080 uM (0.080193μM**)% Activity at given concentration.Float%
20Activity at 0.135 uM (0.135482μM**)% Activity at given concentration.Float%
21Activity at 0.382 uM (0.382139μM**)% Activity at given concentration.Float%
22Activity at 0.607 uM (0.60737μM**)% Activity at given concentration.Float%
23Activity at 1.830 uM (1.83008μM**)% Activity at given concentration.Float%
24Activity at 2.822 uM (2.82235μM**)% Activity at given concentration.Float%
25Activity at 7.703 uM (7.70321μM**)% Activity at given concentration.Float%
26Activity at 11.17 uM (11.1715μM**)% Activity at given concentration.Float%
27Activity at 21.81 uM (21.8083μM**)% Activity at given concentration.Float%
28Activity at 53.02 uM (53.0188μM**)% Activity at given concentration.Float%
29Activity at 106.3 uM (106.269μM**)% Activity at given concentration.Float%
30Activity at 201.0 uM (200.968μM**)% Activity at given concentration.Float%
31Activity at 460.8 uM (460.829μM**)% Activity at given concentration.Float%
32Activity at 1030.4 uM (1030.41μM**)% Activity at given concentration.Float%
33Activity at 2447.4 uM (2447.39μM**)% Activity at given concentration.Float%
34Activity at 5174.9 uM (5174.85μM**)% Activity at given concentration.Float%
35Activity at 12995.4 uM (12995.4μM**)% Activity at given concentration.Float%
36Activity at 29059.9 uM (29059.9μM**)% Activity at given concentration.Float%
37Activity at 64977.0 uM (64977μM**)% Activity at given concentration.Float%
38Activity at 129953.9 uM (129954μM**)% Activity at given concentration.Float%
39Compound QCNCGC designation for data stage: 'qHTS', 'qHTS Verification', 'Secondary Profiling'String

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: DK058080

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: